oasis 1 oral semaglutide 50 mg obesity nejm 2023 results For patients with #obesity, semaglutide, a glucagon-like peptide-1 receptor agonist, is approved for weight management as a once-weekly subcutaneous injection. In a previous trial, at a dose of oasis 1 oral semaglutide 50

Discuss your medical history Once your appointment is scheduled, youll meet with a Forum Health provider who will review your health history and recommend blood work if necessary

Its available under the brand names Mounjaro (for diabetes) and Zepbound (for obesity)

There are several other GLP-1 receptor agonists available on the market, and it can be helpful to compare semaglutide to these other options to determine which brand is right for you

Staying well-hydrated, eating light and balanced meals, and avoiding heavy or greasy foods may help reduce early side effects like nausea

Bloating and its relationship to diarrhea Bloating frequently accompanies or precedes diarrhea episodes during retatrutide use